NASDAQ:CTRV - ContraVir Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.01 +0.05 (+5.21 %)
(As of 07/20/2018 12:31 PM ET)
Previous Close$0.96
Today's Range$0.96 - $1.03
52-Week Range$0.94 - $6.60
Volume1,900 shs
Average Volume156,375 shs
Market Capitalization$10.15 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81
ContraVir Pharmaceuticals logoContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.

Receive CTRV News and Ratings via Email

Sign-up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTRV
CUSIPN/A
Phone732-902-4000

Debt

Debt-to-Equity RatioN/A
Current Ratio1.62
Quick Ratio1.62

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.27 per share
Price / Book3.74

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-154.66%
Return on Assets-48.40%

Miscellaneous

Employees21
Outstanding Shares10,690,000
Market Cap$10.15

ContraVir Pharmaceuticals (NASDAQ:CTRV) Frequently Asked Questions

What is ContraVir Pharmaceuticals' stock symbol?

ContraVir Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTRV."

When did ContraVir Pharmaceuticals' stock split? How did ContraVir Pharmaceuticals' stock split work?

ContraVir Pharmaceuticals shares reverse split on the morning of Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 28th 2018. An investor that had 100 shares of ContraVir Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were ContraVir Pharmaceuticals' earnings last quarter?

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) posted its quarterly earnings results on Friday, May, 13th. The biopharmaceutical company reported ($1.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.80) by $0.68. View ContraVir Pharmaceuticals' Earnings History.

What price target have analysts set for CTRV?

1 analysts have issued 12-month target prices for ContraVir Pharmaceuticals' stock. Their forecasts range from $32.00 to $32.00. On average, they expect ContraVir Pharmaceuticals' share price to reach $32.00 in the next twelve months. This suggests a possible upside of 3,068.3% from the stock's current price. View Analyst Ratings for ContraVir Pharmaceuticals.

What is the consensus analysts' recommendation for ContraVir Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraVir Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of ContraVir Pharmaceuticals' key competitors?

Who are ContraVir Pharmaceuticals' key executives?

ContraVir Pharmaceuticals' management team includes the folowing people:
  • Mr. James R. Sapirstein, CEO & Director (Age 57)
  • Dr. Theresa Matkovits, Chief Operating Officer (Age 51)
  • Dr. John Z. Sullivan-Bolyai, Part-Time Consultant & Member of Scientific Advisory Board (Age 70)
  • Mr. John T. Cavan, Chief Financial Officer (Age 60)
  • Dr. Robert T. Foster BSc (Pharm), Pharm.D., Ph.D., Chief Scientific Officer (Age 60)

Has ContraVir Pharmaceuticals been receiving favorable news coverage?

News headlines about CTRV stock have trended somewhat positive this week, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ContraVir Pharmaceuticals earned a news sentiment score of 0.09 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.07 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of ContraVir Pharmaceuticals?

Shares of CTRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ContraVir Pharmaceuticals' stock price today?

One share of CTRV stock can currently be purchased for approximately $1.01.

How big of a company is ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals has a market capitalization of $10.15 million. ContraVir Pharmaceuticals employs 21 workers across the globe.

How can I contact ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals' mailing address is 399 THORNALL STREET FIRST FLOOR, EDISON NJ, 08837. The biopharmaceutical company can be reached via phone at 732-902-4000 or via email at [email protected]


MarketBeat Community Rating for ContraVir Pharmaceuticals (NASDAQ CTRV)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  214
MarketBeat's community ratings are surveys of what our community members think about ContraVir Pharmaceuticals and other stocks. Vote "Outperform" if you believe CTRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.